← All organizations
Highest phase reached
Phase 4
Timeline
2000s
- Jun 1, 2002
Celltrion— Founded
2010s
- Dec 14, 2018
trastuzumab— Marketing Organization
- Dec 14, 2018
trastuzumab— NDA Secondary Org
Drugs by trial phase (47 distinct, 78 trials)
Phase 4 (6 own, 0 via acquisition)
Phase 3 (23 own, 0 via acquisition)
Phase 2 (4 own, 0 via acquisition)
Phase 1 (14 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Adenocarcinoma of Lung
- Arthritis
- Arthritis, Rheumatoid
- Breast Neoplasms
- Cardiomyopathies
- Cardiomyopathy, Hypertrophic
- Colitis
- Colitis, Ulcerative
- Coronavirus Infections
- Crohn Disease
- Hypertrophy
- Infections
- Influenza, Human
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Psoriasis
- Severe Acute Respiratory Syndrome
- Spondylitis
- Spondylitis, Ankylosing
- Stomach Neoplasms
- Ulcer
- Urticaria
Marketed drugs (32)
Recent trials (50)
- NCT07128654Lead sponsorPhase 1Sep 17, 2025
- NCT07200986Lead sponsorPhase 1Sep 17, 2025
- NCT07158346Lead sponsorPhase 1Aug 18, 2025
- NCT06952478Lead sponsorPhase 3Aug 12, 2025
- NCT07093476Lead sponsorPhase 3Jul 18, 2025
- NCT06951828Lead sponsorPhase 1May 30, 2025
- NCT06630559Lead sponsorPhase 3Apr 30, 2025
- NCT06687928Lead sponsorPhase 1Feb 28, 2025
- NCT06687928OfficialPhase 1Feb 28, 2025
- NCT06939595Lead sponsorPhase 3Jan 30, 2025
- NCT06738719Lead sponsorPhase 3Jan 20, 2025
- NCT06989723CollaboratorPhase 4Jan 1, 2025
- NCT06571591Lead sponsorPhase 3Aug 27, 2024
- NCT06113913CollaboratorPhase 4Jan 31, 2024
- NCT07054970Lead sponsorPhase 1Jan 12, 2024
Details
- Founded
- Incheon, KR Jun 1, 2002
- Last known activity
- Jan 21, 2026